BAYZED HEALTH

2609
2.4000.21% ( -0.005 )
Delay Closed: Nov 16, 16:08:11

Overview

BAYZED HEALTH (2609)

Bayzed Health Group Inc operates and manages a network of hospitals that provides oncology medical and healthcare services in the People’s Republic of China. Th...

Open
2.410
High
2.430
Low
2.365
Prev. Close
2.405
Volume
1.76M
Turnover
4.22M
Avg Price
2.398
Bid/Ask Ratio
-97.44%
Amplitude
2.70%
52wk High
7.040
Volume Ratio
0.58
Turnover Ratio
0.13%
52wk Low
2.365
HK Mkt Cap
3.16B
Market CapHKD
3.16B
P/ETTM
94.51
P/EDynamic
95.31
P/EStatic
--
EPSTTM
0.0254
EPSDynamic
0.0252
EPSStatic
--
BVPS
1.33
P/B
1.81
HK Shares
1.32B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.32B
Min lot size
600
Currency
HKD

Daily Events

  1. Nov, 9

    Bayzed Health reversed early gains, opening at HK$2.740 at the session high before sliding to HK$2.555 by 15:46 BJ and closing at HK$2.615, down about 2.97% from the prior HK$2.695 close on HK$12.55 million turnover, extending a roughly 5% single-day decline in the previous session after shareholder Zhu Hongbing cut 1.8396 million shares at about HK$3.16. Interim results showed profit attributable to shareholders of HK$14.418 million against a year-earlier loss, with revenue of RMB584.45 million up only 1.7% and Q2 net profit up 155% year on year, yet a 2.47% net margin leaves the stock on 102.97x PE and 1.97x PB. The shares are down 32.78% year to date, 63.93% below the HK$7.25 52-week high and just 3.56% above the HK$2.525 low set on November 2, trading beneath both the MA20 of 2.704 and MA60 of 2.882, though a 0.36% turnover rate points to limited broad capitulation.

  2. Nov, 3

    Bayzed Health rebounded off its low but still closed down 1.87% at HK$2.63, weighed by a shareholder sell-down: Zhu Hongbing cut 1.8396 million shares at about HK$3.16. It opened at HK$2.65, printed an intraday high of HK$2.66 in the morning session, then slid to HK$2.525 at 14:57 BJ, close to its 52-week low, before recovering to HK$2.63 on 4.38 million shares worth HK$11.42 million. Interim fundamentals ran the other way: first-half revenue rose 1.7% to RMB 584.45 million, profit attributable to shareholders of RMB 18.47 million marked a swing back into profit, and adjusted profit rose 96.8%; second-quarter net profit was HK$8.33 million, up 155% year on year. Against that, valuation and price position remain weak: 103.56x PE and 1.98x PB, with the price below both the MA20 of HK$2.763 and the MA60 of HK$2.904, down 32.39% year to date and 64.27% below the HK$7.36 52-week high. Though turnover of just 0.33% suggests supply at the lows was only partly absorbed.

  3. Oct, 27

    Bayzed Health staged an intraday rebound, sliding to a 2.635 low at 10:54 before grinding back to close at the 2.700 session high, up 0.37% from the prior 2.690 close. The resilience tracks the interim turnaround: H1 net profit attributable reached RMB 18.47 million with adjusted profit up 96.8% year on year, while Q2 revenue came in at HKD 337.5 million, up 7.19%. Yet the price still sits below its MA20 of 2.83 and MA60 of 2.937, down 30.59% year to date, 70.3% below the 52-week high of 9.09 set on 16 October 2025 and only 5.26% above the 2.565 low of 21 October. Reductions by Zhu Hongbing of 1.8396 million shares near HKD 3.16 and by Shanghai Xukun of 5 million shares near HKD 2.95 cap the upside, though a 106x PE and 2.03x PB suggest elevated expectations are already priced in.

  4. Oct, 22

    Bayzed Health closed down 1.1% at HK$2.69 on 3.82 million shares worth about HK$10.18 million, weighed by a run of shareholder disposals: Zhu Hongbing cut 1.8396 million shares near HK$3.16 and Shanghai Xukun trimmed 5 million shares near HK$2.95. The session traced a dip-and-recover shape, spiking to HK$2.755 at 10:18 BJ before sliding to HK$2.565 at 15:39 BJ, a fresh 52-week low, then clawing back to HK$2.69 into the close. Fundamentals and price diverge, with interim revenue up 1.7% to RMB 584.45 million, a swing to RMB 18.47 million attributable profit and adjusted profit up 96.8%, while Q2 net profit jumped 155.02% year on year to HK$8.33 million; yet the PE stands at 105.93x and the stock is down 30.85% year-to-date, 70.41% below its 52-week high of HK$9.09 and beneath both its MA20 of HK$2.856 and MA60 of HK$2.949. Turnover was just 0.29%, though, so thin liquidity can amplify moves.

  5. Oct, 15

    Pressured by shareholder selldowns, Bayzed Health (2609.HK) spiked and faded through the Hong Kong morning before steadying late, closing at HK$2.650 after an intraday high of HK$2.765 at 10:17 and a low of HK$2.620 at 14:09, the latter matching its 52-week trough. Zhu Hongbing cut 1.8396 million shares at about HK$3.16 and Shanghai Xukun trimmed 5 million shares near HK$2.95, both above the current price. Fundamentals moved the other way: Q2 revenue of HK$337.5 million rose 7.19% year on year, net profit of HK$8.33 million climbed 155%, operating profit grew more than 34-fold and the interim result swung to profit, yet at roughly 105x PE the shares are down 31.23% year to date, below the MA20 of 2.906 and MA60 of 2.964. Turnover was thin though, at only HK$7.73 million with a 0.21% turnover rate.

News